Viral suppression among children and their caregivers living with HIV in western Kenya by Humphrey, John M. et al.
RESEARCH ARTICLE
Viral suppression among children and their caregivers living with
HIV in western Kenya
John M Humphrey1§ , Becky L Genberg2 , Alfred Keter3, Beverly Musick4 , Edith Apondi5 ,
Adrian Gardner1, Joseph W Hogan6 and Kara Wools-Kaloustian1
§Corresponding author: John M Humphrey, 545 Barnhill Drive, EH 421, Indianapolis, Indiana 46202, USA. Tel: +1 (317) 274-8115. (humphrjm@iu.edu)
Abstract
Introduction: Despite the central role of caregivers in managing HIV treatment for children living with HIV, viral suppression
within caregiver–child dyads in which both members are living with HIV is not well described.
Methods: We conducted a retrospective analysis of children living with HIV <15 years of age and their caregivers living with
HIV attending HIV clinics affiliated with the Academic Model Providing Access to Healthcare (AMPATH) in Kenya between
2015 and 2017. To be included in the analysis, children and caregivers must have had ≥1 viral load (VL) during the study per-
iod while receiving antiretroviral therapy (ART) for ≥6 months, and the date of the caregiver’s VL must have occurred
90 days from the date of the child’s VL. The characteristics of children, caregivers and dyads were descriptively summarized.
Multivariable logistic regression was used to estimate the odds of viral non-suppression (≥ 1000 copies/mL) in children, adjust-
ing for caregiver and child characteristics.
Results: Of 7667 children who received care at AMPATH during the study period, 1698 were linked to a caregiver living with
HIV and included as caregiver–child dyads. For caregivers, 94% were mothers, median age at ART initiation 32.8 years, median
CD4 count at ART initiation 164 cells/mm3 and 23% were not virally suppressed. For children, 52% were female, median age
at ART initiation 4.2 years, median CD4 values at ART initiation were 15% (age < 5 years) and 396 cells/mm3 (age ≥ 5 years),
and 38% were not virally suppressed. In the multivariable model, children were found more likely to not be virally suppressed
if their caregivers were not suppressed compared to children with suppressed caregivers (aOR = 2.40, 95% CI: 1.86 to 3.10).
Other characteristics associated with child viral non-suppression included caregiver ART regimen change prior to the VL, care-
giver receipt of a non-NNRTI-based regimen at the time of the VL, younger child age at ART initiation and child tuberculosis
treatment at the time of the VL.
Conclusions: Children were at higher risk of viral non-suppression if their caregivers were not virally suppressed compared to
children with suppressed caregivers. A child’s viral suppression status should be closely monitored if his or her caregiver is not
suppressed.
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1 | INTRODUCTION
The scale-up of antiretroviral therapy (ART) in sub-Saharan
Africa has improved survival of both children living with HIV
and their parents and caregivers living with HIV [1]. In these
relationships, caregivers must assume responsibility for their
own HIV management as well as their child’s management.
However, both individuals may be vulnerable to medical, eco-
nomic and psychosocial stressors that may act as barriers to
maintaining viral suppression and health for each individual
and the relationship as a whole, suggesting the potential
importance of family-centred HIV services for these care-
giver–child dyads [2,3]. Yet, despite the central role of care-
givers in the management of children living with HIV and the
common barriers to viral suppression they may both
encounter, the association between viral non-suppression in
caregiver–child dyads is not well understood.
Various studies describing caregiver–child interactions in
the context of HIV, particularly in resource-limited settings,
suggest the possibility that viral suppression in children and
their caregivers is associated. Poverty, substance abuse, physi-
cal and mental illness, and perceived lack of social support
may jeopardize adherence to ART for both caregivers and
children [2,4]. Having a caregiver other than the mother, expe-
riencing a change in caregiver, and not having a caregiver
attend a child’s clinic appointment have been associated with
lower adherence and higher odds of virologic failure among
children and adolescents [5–8]. A mother’s attitude and beha-
viour regarding her own ART adherence may also influence
her adherence practices towards her child [9]. Such influences
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could be positive (e.g. modelling good adherence and beliefs
about ART efficacy) or negative (e.g. externalizing feelings of
stigma and guilt, concerns over ART side effects, forgetting
ART doses or medication fatigue), and dynamic over time as
children gain independence and family structures evolve
[10,11]. Children may miss ART doses if their caregivers are
unavailable or struggling to manage their own HIV infection
and associated conditions [2,12]. HIV-related stigma and
disclosure concerns may further inhibit caregivers from
administering ART to their children or bringing them to clinic
[13–17].
HIV viral load (VL) testing has recently been introduced in
Kenya and other countries in sub-Saharan Africa for routine
treatment monitoring [18–20]. This presents a novel opportu-
nity to examine caregiver–child viral suppression in this region.
Given the risk of HIV drug resistance and HIV disease pro-
gression in the setting of HIV viraemia, characterizing the dri-
vers of viral non-suppression in children is important [21]. The
objective of this study is to describe the association between
child and caregiver viral suppression and the factors that influ-
ence viral non-suppression in children.
2 | METHODS
2.1 | Study design
This retrospective cohort study used electronic medical
record data from children living with HIV and their adult care-
givers living with HIV who received HIV care at the Academic
Model Providing Access to Healthcare (AMPATH) programme
in western Kenya between 2015 and 2017. This study was
approved by the Institutional Research and Ethics Committee
at Moi University in Kenya and Indiana University IRB.
Patient-level consent was waived by the regulatory bodies
because the data were collected as part of routine care and
were de-identified prior to analysis.
2.2 | Study setting and population
AMPATH is a USAID-funded HIV care and treatment pro-
gramme situated in a generalized HIV epidemic setting in
western Kenya [22]. AMPATH is a participating site in the
International Epidemiology Databases to Evaluate AIDS East
Africa consortium [23]. The county-level HIV prevalence in the
AMPATH catchment ranges from 1.6% to 20.7% among adults
≥15 years of age. In these counties, there are an estimated
446,693 HIV-positive adults ≥15 years of age and 36,743
HIV-positive children 0 to 14 years of age, with ART coverage
ranging from 47% to 100% for adults and 49% to 98% for
children as of 2017 [24]. Since 2001, AMPATH has enrolled
over 150,000 patients living with HIV at Ministry of Health
facilities across western Kenya and currently provides HIV
care to approximately 85,000 patients, including over 7500
children [25,26]. All facilities provide standard of care HIV
treatment services based on national guidelines, which in
2015 recommended ART initiation for all children ≤10 years
of age and adolescents and adults with CD4 count
<500 cells/mm3 [19]. The WHO Option B+ policy recom-
mending lifelong ART for all pregnant women living with HIV
was adopted by the Kenya Ministry of Health and AMPATH in
2014 [19]. In 2016, AMPATH transitioned to universal ART
eligibility [27]. Recommended first-line ART at the time of the
study was lopinavir-based for children <3 years of age and
efavirenz-based for children three to fourteen years of age
and adults ≥15 years of age.
Within the AMPATH programme there is a dedicated paedi-
atric HIV clinic at Moi Teaching and Referral Hospital with
paediatric-dedicated clinical officers and paediatricians. How-
ever, at all other facilities, the same clinical officers treat both
children and adults either in separate or combined adult/pae-
diatric clinics. The study population included all children living
with HIV and their caregivers living with HIV who attended
an AMPATH affiliated HIV clinic at any time from 1 January
2015 to 14 February 2017. Routine VL monitoring was imple-
mented for all patients at AMPATH during this period, replac-
ing the previous recommendation for immunologic monitoring.
At the time of the study, WHO and Kenyan HIV treatment
guidelines recommended VL testing six months after ART initi-
ation, and if ≤1000 copies/mL, annually thereafter [27,28].
Individuals with a VL ≥1000 copies/mL were recommended to
have the VL test repeated after a minimum of three months
of enhanced adherence counselling and support. CD4 testing
was recommended at baseline, but not routinely thereafter,
for individuals on ART with access to VL testing [19].
Caregiver–child dyads were selected for the study accord-
ing to the following criteria: First, children were included in
the study if they were: (1) <15 years of age on or after 1 Jan-
uary 2015 (study start date); (2) living with HIV and enrolled
in care at AMPATH; (3) receiving ART for at least six months
prior to 14 February 2017 (database closure); and (4) docu-
mented to have at least one VL measure while receiving ART
for at least six months. We then excluded all children who
were not linked to any caregiver in the medical record. Care-
giver was defined as any individual living with HIV and catego-
rized as mother, father, aunt, uncle, grandparent, stepparent,
foster parent, guardian or caretaker. Although siblings could
also act as caregivers in the Kenya context (e.g. for orphaned
children whose parent(s) had died of HIV), the medical record
did not contain information to substantiate siblings’ status as
caregivers so were not included in the caregiver definition
[29]. Subsequently, we included caregivers according to the
above criteria 2 to 4 used for children, along with the
additional criterion that each caregiver has at least one VL
measure 90 days from the date of the child’s VL measure
during the study period. In the event that there was more
than one eligible VL pair for a given dyad during the study
period, we sampled the first chronological caregiver–child VL
pair to serve as the unit of analysis for each individual. For
caregivers linked to more than one child, we included each
child in the analysis so that, for example, a caregiver linked to
two children would be considered two caregiver–child dyads
with the caregiver counted twice. For children linked to multi-
ple caregivers, the mother was preferentially selected, fol-
lowed by the father. In western Kenya and other contexts in
sub-Saharan Africa, mothers are commonly the primary care-
givers for children living with HIV [5,30,31]. We elected to
restrict our sample to those caregiver–child VLs that occurred
within 90 days of one another, as we assumed this to be a
reasonable period in which a temporal association between
caregiver–child viral suppression could be evaluated. Our deci-
sion to include VL measures that occur at least six months
after initiating ART is also consistent with World Health
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Organization (WHO) and Kenyan HIV treatment guidelines, as
elevated VL measures within six months may represent nor-
mal values along the continuum of VL decline for patients with
adequate adherence after initiating ART [27,32]. Finally, we
included children that were <15 years of age because age
≥15 is an established cutoff used to define “young adults” or
“adults” according to the Kenyan Ministry of Health and other
international health agencies [27,33–35].
2.3 | Data management
We used clinical and viral load data available in the AMPATH
electronic medical record (EMR) that was collected during
routine care initially on paper-based forms and from 2016 by
point-of-care data entry [36]. The demographic section of the
EMR contains a “relationships” function that enables the user
to manually enter the names and medical record numbers of
other AMPATH patients (e.g. spouses, children, other family
members/caregivers) and designate the type of relationship
the linkage represents (e.g. parent/child, sibling/sibling, grand-
parent/grandchild, etc.). These relationship links are recorded
in the EMR by clinicians as part of routine clinical documenta-
tion. We used this linkage data to identify the caregiver–child
dyads in our study. These data were de-identified prior to
analysis.
2.4 | Statistical analysis
The primary outcome measure was viral non-suppression
among children, defined as ≥1000 copies/mL. The following
independent variables were included for caregivers and chil-
dren: Enrolment in HIV care – sex, mother/father vital status,
caregiver type, total number of children each caregiver has
(includes HIV-positive children included and excluded from the
study, as well as children who are HIV-negative); ART initiation
– age, WHO stage/CDC class, CD4 count/per cent; Character-
istics during the study period – proportion of caregivers that
attended same clinic as their linked children, total number of
VL measures available for each individual, facility type (Moi
Teaching and Referral Hospital vs. other); Characteristics at the
time of the VL pair selected for analysis – age, pregnancy status
(caregiver only), tuberculosis (TB) treatment status, number of
days between caregiver and child VLs selected for analysis,
antiretroviral (ARV) base class, ART line (according to Kenyan
national treatment guidelines [27]), whether an ARV base class
switch occurred due to treatment failure at any time prior to
the VL during the study period, and whether an ART regimen
change occurred for any reason (except dose changes) at any
time prior to the VL during the study period.
Logistic regression model fitted using generalized estimating
equations (GEE) was used to calculate unadjusted odds ratios
(OR) and 95% confidence intervals (CI) for independent vari-
ables to assess their associations with viral non-suppression in
children. A multivariable logistic regression model fitted using
the same approach was then constructed to estimate the
adjusted association between child viral non-suppression and
caregiver and child characteristics that were significant in the
bivariable model [37–39]. The bivariable and multivariable
models were set-up so that the child viral suppression status
was the dependent variable and the caregiver suppression sta-
tus was the independent variable. The effect of the caregiver
suppression status was adjusted for the following caregiver
and child characteristics: sex, age (years) at ART initiation,
time (years) on ART, being on TB treatment at the time of the
VL, WHO stage/CDC class at ART initiation, CD4 count or %
at ART initiation, NNRTI base class at the time of the VL, ART
regimen change for any reason before the VL, VL not sup-
pressed, type of caregiver, number of children at the time of
the VL (caregiver only), pregnant at the time of the VL (care-
giver only), MTRH facility, caregiver vital status (child only)
and the interaction between age at ART initiation and time on
ART. GEE using exchangeable correlation structure and robust
variance estimation was used to handle the effect of cluster-
ing of children within caregiver units in the model.
3 | RESULTS
A total of 7667 children living with HIV received care at an
AMPATH clinic at least once during the study period (Figure 1).
Of these, 5260 met the inclusion criteria, and of those, 2906
were linked to a caregiver living with HIV who also received
care at an AMPATH clinic during the study period. After elimi-
nating linked caregivers who did not meet the inclusion criteria
(37% of caregivers were eliminated because they did not have a
VL 90 days of the child VL), a total of 1698 caregiver–child
dyads were eligible for the analysis. The age at ART initiation
and proportion of females were similar between children
included in the analysis and all children excluded from the analy-
sis, as well as among the subset of children excluded because
they did not have a link to a caregiver living with HIV. The distri-
bution of dyad types was: mother–daughter (49%), mother–son
(45%), father–son (3%) and father–daughter (2%).
3.1 | Caregiver characteristics
There were 1639 unique caregivers included in the analysis,
among whom 94% were mothers (Table 1). At enrolment, 3%
(n = 54) of caregivers were linked to more than one child liv-
ing with HIV, with 50 linked to two children, three linked to
three children, and one linked to four children. Caregivers had
a median of three children in total (with and without HIV). At
ART initiation, the median caregiver age was 32.8 years. Care-
givers’ median CD4 count (interquartile range [IQR]) at ART
initiation was 164 (86 to 258) cells/mm3 among those with
available data and the majority (88%) had a CD4 count
≤350 cells/mm3. Among caregivers with available WHO stage
at ART initiation, 36% had Stage 3 or 4 disease. During the
study period, caregivers attended the same clinic as their
linked child in 99% of cases, with the caregiver bringing the
child to clinic at least once during the study period in 94% of
cases. Prior to the date of the caregiver VL during the study
period, less than 1% of caregivers experienced an ARV base
class switch due to treatment failure, while 8% experienced an
ART regimen change for any reason. At the time of the care-
giver VL, caregivers’ median age was 38.6 years, 0.7% were
pregnant and 0.7% were on TB treatment. The median time
on ART at the time of the VL was 5.7 years. A total of 89% of
caregivers were receiving non-nucleoside reverse transcrip-
tase inhibitor (NNRTI)-based ART and 89% of ART regimens
were categorized as first line. The VL was not suppressed in
23% of caregivers.
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3.2 | Child characteristics
For children, 52% of 1698 were female (Table 2). At ART ini-
tiation, the median child age was four years and 93% were
<10 years of age, and 3% (n = 52) were linked to more than
one caregiver. Among children with available parental vital
status data at enrolment, the mother was deceased in 6%
and father was deceased in 27%. At ART initiation, the WHO
stage/CDC class was Stage 3 or 4/class B or C in 46% of
children with available data. Among children <5 years of age,
the CD4% at ART initiation was 15% (IQR 10 to 22); for chil-
dren ≥5 years of age, the median CD4 count was 396 cells/
mm3 (IQR 234 to 686). Two-thirds of children with available
data had a CD4% >25% (<5 years) or >350 cells/mm3
(>5 years) at ART initiation. Prior to the date of the child VL,
0.8% of children experienced an ARV base class switch due
to treatment failure and 5.2% experienced an ART regimen
change for any reason. At the time of the child VL used in
the analysis, the median child age was 9.7 years and 0.8%
were on TB treatment. The median time on ART for children
at the time of the VL ranged from 1.2 years for children 0 to
2 years of age to 5.7 years for children 10 to 14 years of
age. A total of 94% of children were receiving NNRTI-based
ART and 96% of children were categorized as receiving first-
line ART. The VL was not suppressed in 38% of children.
Among children on ART ≥6 months and with ≥1 VL available
measure who were excluded from the analysis because they
did not have a link to an HIV-positive caregiver (n = 2354;
see Figure 1), the VL was not suppressed in 33% (n = 1576;
p < 0.001 compared to children included in the analysis).
Additionally, viral suppression among excluded children with
documented orphan status (n = 1439, defined as mother or
both parents deceased and using the earliest VL measure
available during the study period) was 68%, compared to
HIV-positive children < 15 years of age
and in care on or after 1 January 2015
N = 7667
Children receiving ART for ≥6 months
prior to database closure (14 February 2017)
N = 6477
Children with ≥1 viral load measure
after receiving ART for ≥6 months
N = 5260
Children have no link to
an HIV-positive caregiver
N = 2354
Children have link to an
HIV-positive caregiver
N = 2906
Caregivers receiving ART for ≥6 months
prior to database closure (14 February 2017)
N = 2554 caregiver-child dyads
Caregivers with ≥1 viral load measure
after receiving ART for ≥6months
N = 2147 caregiver-child dyads
Caregivers with ≥1 viral load ± 90
days of their child’s viral load measure
N = 1698 caregiver-child dyads
Figure 1. Caregiver–child dyad selection.
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64% for children without documented orphan status
(n = 885) (p = 0.04).
3.3 | Viral load characteristics
There was a median (IQR) of 2 (2 to 3) available VL mea-
sures each for caregivers and children during the study
Table 1. Characteristics of caregivers
Characteristic
N = 1639,
n (%)
Female 1551 (95%)
Age at ART initiation, median years (IQR) 32.8 (28.5 to 37.2)
Age at VL, median years (IQR) 38.6 (33.7 to 43.3)
Time on ART, median years (IQR) 5.7 (3.6 to 7.9)
Type of caregiver
Mother 1535 (94%)
Father 81 (4.9%)
Othera 23 (1.4%)
Number of children at
enrolment, median (IQR)
3 (2 to 5)
Pregnant at VLb 11 (0.7%)
On TB treatment at VL 11 (0.7%)
Facility
MTRH 333 (20%)
Other 1306 (80%)
WHO stage at ART initiation
Stage 1 or 2 985 (60%)
Stage 3 or 4 550 (34%)
Missing 104 (6.4%)
CD4 count at ART initiation, median (IQR) 164 (86 to 258)
≤350 875 (53%)
>350 119 (7.3%)
Missing 645 (39%)
ARV base class at VL
NNRTI 1459 (89%)
PI 178 (11%)
Other (i.e. PI + NNRTI or PI + II) 2 (0.1%)
ART line at VL
First line 1461 (89%)
Second line 177 (11%)
Third line 1 (0.1%)
ARV base class switch for
treatment failure before VLc
7 (0.4%)
ART regimen change for any reason before VLd 134 (8.2%)
VL not suppressed 376 (23%)
ART, antiretroviral therapy; ARV, antiretroviral; II, integrase inhibitor;
IQR, interquartile range; MTRH, Moi Teaching and Referral Hospital;
NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhi-
bitor; TB, tuberculosis; VL, viral load; WHO,World Health Organization.
aOther caregiver types include: step-parent (n = 16), guardian (n = 5),
grandparent (n = 1), uncle (n = 1); bproportion expressed among female
caregivers only (n = 1551); cindicates any ART switch due to failure from
first- to second-line or from second- to third-line before the VL date
according to Kenya HIV treatment guidelines; dexcludes dose change.
Table 2. Characteristics of children
Characteristic
N = 1698,
n (%)
Female 885 (52%)
Age at ART initiation
0 to 2 years 621 (36%)
3 to 5 years 502 (30%)
6 to 9 years 463 (27%)
10 to 14 years 112 (6.6%)
Age at VL
0 to 2 years 85 (5.0%)
3 to 5 years 236 (14%)
6 to 9 years 586 (34%)
10 to 14 years 791 (47%)
Time on ART, median years (IQR)
0 to 2 years 1.2 (0.8 to 1.7)
3 to 5 years 3.0 (1.9 to 4.0)
6 to 9 years 4.9 (2.8 to 6.1)
10 to 14 years 5.7 (3.7 to 7.6)
Caregiver vital status
Mother deceased (n = 1093
with available data)
68 (6.2%)
Father deceased (n = 1063
with available data)
288 (27%)
Mother or father deceased
(n = 1189 with
available data)
326 (27%)
On TB treatment at VL 14 (0.8%)
WHO stage/CDC class at ART initiation
Stage 1 or 2/Class N or A 700 (41%)
Stage 3 or 4/Class B or C 602 (36%)
Missing 396 (23%)
CD4 % at ART initiation for children
<5 years, median (IQR) (n = 450
with available data)
15 (10 to 22)
CD4 count at ART initiation for
children ≥5 years, median (IQR)
(n = 349 with available data)
396 (234 to 686)
CD4 % at ART initiation
>25 for children
<5 years|CD4 count at
ART initiation
>350 for children aged ≥5 years
No 519 (31%)
Yes 280 (17%)
Missing 899 (53%)
ARV base class at VL
NNRTI 1590 (94%)
PI 108 (6.4%)
ART line at VL
First line 1626 (96%)
Second line 72 (4.2%)
ARV base class switch for
treatment failure before VLa
14 (0.8%)
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period. The median (IQR) number of days between the care-
giver and child VL measures used for analysis was 5 (0 to
55) days out of a maximum of 90 days according to the
inclusion criteria. The viral suppression status (<1000 copies/
mL) for all 1698 caregiver–child dyads was: caregiver and
child both suppressed (n = 880 dyads, 52%), caregiver sup-
pressed and child not suppressed (n = 430 dyads, 25%),
caregiver not suppressed and child suppressed (n = 166
dyads, 10%), and caregiver and child both not suppressed
(n = 222 dyads, 13%).
3.4 | Associations with viral non-suppression in
children
In Table 3, caregiver and child characteristics that were signif-
icantly associated (p ≤ 0.05) with child viral non-suppression
in the bivariable model were included in the multivariable
model. The sex of the caregiver and child was also included in
the multivariable model despite not being statistically signifi-
cant in the bivariable model given previously observed sex dif-
ferences in HIV treatment outcomes [40,41]. Children with
caregivers who were not virally suppressed were more than
twice as likely to not be virally suppressed themselves com-
pared to children with suppressed caregivers (adjusted odds
ratio [aOR]=2.40, 95% CI: 1.86 to 3.10; Table 3). Characteris-
tics associated with a higher adjusted odds of viral non-sup-
pression in children included caregiver ART regimen change
for any reason before the VL (aOR = 1.82, 95% CI: 1.21 to
2.72), the child being on TB treatment at the time of the VL
(aOR = 3.32, 95% CI: 1.13 to 9.81). Characteristics associated
with a lower adjusted odds of viral non-suppression in children
included caregiver receipt of an NNRTI-based regimen at the
time of the VL (aOR = 0.69, 95% CI 0.50 to 0.97), and child
age six to nine years (aOR = 0.49, 95% CI 0.27 to 0.89) and
10 to 14 years (aOR = 0.30, 95% CI 0.11 to 0.82) compared
to zero to two years.
4 | DISCUSSION
In our study of children and their caregivers living with HIV,
we found that children had more than twice the odds of not
being virally suppressed if their caregivers were not virally
suppressed, compared to children with suppressed caregivers.
Caregivers experiencing an ART regimen change for any rea-
son before the VL and receiving a non-NNRTI-based regimen
at the time of the VL were both associated with viral non-
suppression in children. In Kenya, non-NNRTI-based regimens
(e.g. protease or integrase inhibitor-based regimens) typically
constitute second- or third-line ART for patients with HIV
viraemia on first-line, NNRTI-based ART [27]. Inadequate
adherence is a common cause of HIV viraemia among adults
receiving first- and second-line ART in sub-Saharan Africa,
and adherence to first-line ART has been shown to be a
strong predictor of adherence to second-line ART [42–44].
Thus, although our study did not directly measure adherence,
it is possible that experiencing an ART regimen change or
being on a non-NNRTI regimen are markers of prior inade-
quate adherence among caregivers that increased the risk of
future inadequate adherence (i.e. at the time of the VL) for
them and their children [42,45]. Young children are uniquely
dependent on caregivers for their ART management, and it is
plausible that caregivers’ adherence practices extended to
their children, increasing the risk of viral non-suppression for
both individuals [9]. Further research is needed to under-
stand the patient and site-level factors (e.g. availability of
counselling and other interventions to enhance adherence)
that contribute to viral non-suppression among dyads, as well
as the potential influence of adherence and drug resistance
[46].
Overall viral suppression among caregivers and children in
our study was suboptimal. The VL was suppressed for both
the caregiver and child in only half of dyads, while 62% of chil-
dren and 77% of caregivers were suppressed overall. These
suppression estimates are lower than current national, facility-
based estimates for children and adults receiving ART in
Kenya at 68% and 86%, respectively, underscoring the vulner-
ability of this population and the importance of understanding
the barriers to viral suppression it experiences [47,48].
Achieving viral suppression for children in sub-Saharan Africa
is especially challenging. Studies have reported lower viral
suppression rates for children and adolescents compared to
adults in Kenya (57% to 66% vs. 63% to 87%) and in other
low- and middle-income countries (60% to 75% vs. 85%), as
well as compared to children and adolescents in high-income
countries (≥ 90%) [49–53]. A range of factors can influence
adherence and viral suppression for children including the
child’s age, familial and socio-economic environment, stigma,
disclosure, and the physical and mental health status of chil-
dren and caregivers [3,10,54,55]. Consistent with prior stud-
ies, we found that older child age was protective against viral
non-suppression compared to child age ≤2 years [56–58]. This
could reflect behavioural changes during childhood such as
younger children refusing to take medications or the positive
effects of HIV disclosure to older children, the effect of ART
dosing frequency (i.e. twice daily dosing of lopinavir-based
ART in children <3 years vs. once daily efavirenz-based ART
for children ≥3 years and ≥35 kg), or biologic factors such as
slower rates of viral suppression in infants compared to older
children.
Additionally, children in our study who were receiving TB
treatment at the time of the VL were three times more likely
to not be virally suppressed compared to children not receiv-
ing TB treatment. This finding may be a statistical artefact
given that only 0.8% of children were on TB treatment at the
Table 2. (Continued)
Characteristic
N = 1698,
n (%)
ARV regimen change for any
reason before VLb
89 (5.2%)
VL not suppressed 652 (38%)
ART, antiretroviral therapy; ARV, antiretroviral; CDC, Centers for Dis-
ease Control; II, integrase inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; PI, protease inhibitor; TB, tuberculosis; VL, viral
load; WHO, World Health Organization.
aIndicates any ART switch from first- to second-line or from second-
to third-line before the VL date according to Kenya HIV treatment
guidelines; bexcludes dose changes.
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time of the VL (with this low percentage related at least in
part the cross-sectional nature of this variable among individu-
als enrolled in HIV care and on ART for ≥6 months). However,
treatment for TB has been associated with a higher risk of
viral non-suppression in two studies of children living with
HIV in South Africa, which may be due to the child receiving
Table 3. Unadjusted and adjusted odds ratios for factors associated with viral non-suppression in children
Characteristic N Unadjusted OR (95% CI) Adjusted OR (95% CI) N = 1608
Caregiver characteristics
Female 1639 1.14 (0.73 to 1.78) 0.84 (0.52 to 1.36)
Age (years) at ART initiation 1635 0.97 (0.96 to 0.99) 0.98 (0.96 to 1.00)
Time (years) on ART 1635 1.00 (0.97 to 1.04) 0.99 (0.94 to 1.04)
Type of caregiver
Mother versus other 1639 0.82 (0.36 to 1.87)
Father versus other 0.66 (0.26 to 1.70)
Number of children at VL 1504 0.98 (0.93 to 1.04)
Pregnant at VL 1551 2.80 (0.82 to 9.63)
On TB treatment at VL 1639 2.83 (0.82 to 9.69) 1.70 (0.49 to 5.84)
MTRH facility 1639 1.00 (0.78 to 1.28)
WHO Stage 3 to 4 at ART initiation
Stage 3 or 4 versus Stage 1 or 2 1639 0.93 (0.75 to 1.15)
Missing versus Stage 1 or 2 1.05 (0.70 to 1.58)
CD4 count at ART initiation >350
Yes versus no 1639 0.99 (0.67 to 1.46) 1.23 (0.81 to 1.86)
Missing versus no 1.21 (0.98 to 1.49) 1.17 (0.94 to 1.47)
NNRTI base class at VL (vs. PI/other regimen) 1639 0.65 (0.47 to 0.88) 0.69 (0.50 to 0.97)
ART regimen change for any reason before VL 1639 2.89 (2.02 to 4.13) 1.82 (1.21 to 2.72)
VL not suppressed 1639 2.72 (2.15 to 3.43) 2.40 (1.86 to 3.10)
Children characteristics
Female 1639 0.89 (0.73 to 1.08) 0.86 (0.70 to 1.06)
Age (years) at ART initiation
0 to 2 years 1639 Ref. Ref.
3 to 5 years 0.59 (0.33 to 1.04) 0.71 (0.39 to 1.30)
6 to 9 years 0.39 (0.22 to 0.68) 0.49 (0.27 to 0.89)
10 to 14 years 0.24 (0.09 to 0.63) 0.30 (0.11 to 0.82)
Time (years) on ART 1639 0.98 (0.92 to 1.04) 1.01 (0.93 to 1.10)
Caregiver vital status
Mother or father deceased versus neither mother nor father deceased 1531 0.96 (0.73 to 1.25)
Missing versus none 0.95 (0.75 to 1.19)
On TB treatment at VL 1639 3.36 (1.01 to 11.22) 3.32 (1.13 to 9.81)
WHO stage at ART initiation
Stage 3/4 & CDC Class B/C versus Stage 1/2 & Class A/N 1639 1.06 (0.85 to 1.32)
Missing versus Stage 1/2 & Class A/N 1.13 (0.88 to 1.46)
CD4 % at ART initiation >25 for children <5 years|CD4 count at
ART initiation >350 for children aged >5 years
Yes versus no 1612 0.77 (0.58 to 1.04) 0.76 (0.55 to 1.05)
Missing versus no 0.98 (0.79 to 1.22) 0.97 (0.76 to 1.24)
NNRTI base class at VL (vs. PI/other regimen) 1639 1.15 (0.77 to 1.72)
ART regimen change for any reason before VL 1639 0.89 (0.57 to 1.38)
Age at ART initiation 9 time (years) on ART
0 to 2 years 1639 Ref. Ref.
3 to 5 years 1.05 (0.95 to 1.15) 1.03 (0.93 to 1.14)
6 to 9 years 1.14 (1.01 to 1.28) 1.13 (1.00 to 1.28)
10 to 14 years 1.66 (1.14 to 2.40) 1.68 (1.16 to 2.43)
ART, antiretroviral therapy; ARV, antiretroviral; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; TB, tuberculosis; VL,
viral load; WHO, World Health Organization.
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protease inhibitor-based ART (e.g. pharmacologic interactions
between ritonavir and rifampicin), inadequate ART adherence
due to higher toxicities or pill burden, or biologic factors (e.g.
immune activation in the setting of active TB causing HIV vir-
aemia) [59–62]. Alternatively, the risk of incident TB may have
been higher among children with worsening immune function
due to ongoing viral replication, or among children with late-
onset immune reconstitution inflammatory syndrome following
ART initiation [63].
Our findings suggest that a child’s viral suppression status
should be carefully assessed at the time his or her caregiver
is found not to be virally suppressed. Some barriers to
adherence and viral suppression may be common to both
individuals, and a family-centred management approach,
rather than an individual approach, may be needed to
address these barriers effectively. Differentiated care models
that focus on the needs of families living with HIV are
emerging [64–69]. In South Africa, family clubs are being
used as ART distribution alternatives [64]. In Uganda, imple-
menting weekly clinics where children and adolescents were
treated together with their families improved appointment
adherence, and similar models have been implemented in
urban centres in Kenya and through community groups in
Namibia [65,70]. These care models may offer services that
are better tailored to family issues and more efficient for
programmes and patients [64,71–73]. To date, however,
existing models have focused on clinically stable families and
children with reliable caregivers, and knowledge gaps exist
regarding models for at-risk families [65,72,74,75]. Psychoso-
cial interventions that address stigma, disclosure and mental
health issues will likely play an important role in these mod-
els [3,10,54,55,76].
Our study has strengths and limitations. This study is, to
our knowledge, the first to identify an association between
viral suppression in children and their caregivers who were
both living with HIV. Although others have investigated care-
giver–child interactions that could influence adherence, our
large cohort of caregiver–child dyads enabled us to directly
evaluate the outcome of viral suppression [7–9,77]. The use
of observational programme data carries limitations. Although
the proportions of children included and excluded from the
analysis were similar in terms of sex and age at ART initia-
tion, subject selection may have been biased. Linking care-
givers and children in the AMPATH medical record is an
active process performed by clinicians or counsellors during
routine care, and these individuals may have been less
inclined to link non-mother caregivers to their children in
the medical record. We had limited insight into the roles
caregivers played in their children’s HIV care in our retro-
spective study (e.g. who was responsible for administering a
child’s medications), though understanding these roles is ulti-
mately essential to understanding the meaning of the viral
suppression association we identified. Despite this limited
insight, it is likely that mothers, who comprised the large
majority of caregivers in our study, were in fact responsible
for their children’s HIV management, which is consistent with
other studies in sub-Saharan Africa [5,31]. Finally, adherence
and the factors associated with it are dynamic processes that
can vary over time [78]. We plan to examine the longitudinal
nature of viral suppression among child–caregiver dyads in
future research.
5 | CONCLUSIONS
Among caregiver–child dyads in which both members were liv-
ing with HIV, children were more likely to not be virally sup-
pressed if their caregivers were not virally suppressed,
compared to children with suppressed caregivers. A child’s
viral suppression status should be closely monitored if his or
her caregiver is not virally suppressed.
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